logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

Intellia Therapeutics in the News Intellia Therapeutics ( NTLA ) presented the first demonstration of physiological protein levels of human alpha-1 antitrypsin ( AAT ) in non-human primates (NHPs) following a single administration.  Intellia Therapeutics Liver Gene Insertion Technology Intellia’s...

Read More

December 15, 2020

0

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. FDA granted approval to the Rhythm Pharmaceuticals ( RYTM ) product IMCIVREE™ (setmelanotide) for obesity due to proopiomelanocortin ( POMC ), proprotein convertase subtilisin/Kexin...

Read More

December 29, 2020

0

Cassava Sciences: More Positive News in Alzheimer's Disease

Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences ( SAVA ) , a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. The new data...

Read More

December 30, 2019

0

Vir Biotechnology and GlaxoSmithKline: The European Medicines Agency Started a Review of VIR-7831 for COVID-19

Vir Biotechnology and GlaxoSmithKline in April 2020  In April 2020, Vir Biotechnology and GlaxoSmithKline entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2 (the virus that causes COVID-19). The collaboration uses Vir’s proprietary monoclonal antibody platform...

Read More

April 20, 2021

0

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses bluebird bio ( BLUE )  will retain focus on its severe genetic disease ( SGD ) and will launch its oncology business ( Oncology Newco ) as a new entity. The Board of Directors...

Read More

January 14, 2021

0

Humanigen Inc Product Lenzilumab Combination with CAR T in DLBCL Protects from Severe Cytokine Syndrome

Humanigen Product Lenzilumab Combination with CAR-T At the recommended Phase 2 dose, lenzilumab in combination with CAR-T demonstrated a 100% objective response rate and no severe cytokine release syndrome or severe neurotoxicity Lenzilumab reduced IL-6, CRP, ferritin, MCP-1, IL-8, and...

Read More

April 21, 2021

0

Compugen: Why the Great Expectations from this Firm

The Compugen Story For those who are still asking about the value of Compugen’s ( CGEN ) discoveries our answer is that the best story written about this firm is its own autobiography.   We believe Compugen's accomplishments are extremely...

Read More

January 22, 2021

0

Merck Has Interesting News and Impressive Results

Merck Discontinues Development of COVID-19 Vaccine Candidates Merck ( MRK )  known as MSD outside the United States and Canada announced yesterday that the company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591. This decision follows...

Read More

January 26, 2021

0

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

Sanofi and AstraZeneca MELODY Trial Results for Nirsevimab In March 2017, Sanofi ( SNY ) and AstraZeneca ( AZN ) announced an agreement upon which they develop and commercialize nirsevimab. Under the terms of the agreement, Sanofi will lead commercialization...

Read More

April 27, 2021

0

Forty Seven Continues to Outperform

Forty Seven On December 21, 2018 Prohost picked Forty Seven ( FTSV ) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the...

Read More

January 17, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 16
  • 17
  • 18
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy